search
Back to results

The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

Primary Purpose

Peripheral Arterial Disease

Status
Completed
Phase
Phase 4
Locations
Australia
Study Type
Interventional
Intervention
Ramipril
Sponsored by
Baker Heart Research Institute
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease

Eligibility Criteria

undefined - 70 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Ankle-brachial index of <0.9 at rest in at least one leg History of intermittent claudication (unilateral or bilateral) which was stable for 6 months Evidence of superficial femoral artery stenosis or occlusion on duplex scan Blood pressure <=160/90 mmHg Stable medication regimen for at least 6 months and not previously treated with ACE inhibitors Exclusion Criteria: Limiting coronary artery disease Renal Failure History of hypertension History of type 2 diabetes mellitus

Sites / Locations

  • Alfred Hospital

Outcomes

Primary Outcome Measures

Time to onset of claudication
Total exercise time during a standard treadmill test
Walking ability measured using the standard Walking Impairment Questionnaire

Secondary Outcome Measures

Leg Blood Flow using Duplex Ultrasound

Full Information

First Posted
September 9, 2005
Last Updated
January 28, 2009
Sponsor
Baker Heart Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT00168467
Brief Title
The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease
Official Title
The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Baker Heart Research Institute

4. Oversight

5. Study Description

Brief Summary
One important clinical challenge in older individuals is maintaining mobility in the absence of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility. Conventional therapies have only modest effect in improving symptoms. The investigators hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
40 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Ramipril
Primary Outcome Measure Information:
Title
Time to onset of claudication
Title
Total exercise time during a standard treadmill test
Title
Walking ability measured using the standard Walking Impairment Questionnaire
Secondary Outcome Measure Information:
Title
Leg Blood Flow using Duplex Ultrasound

10. Eligibility

Sex
All
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ankle-brachial index of <0.9 at rest in at least one leg History of intermittent claudication (unilateral or bilateral) which was stable for 6 months Evidence of superficial femoral artery stenosis or occlusion on duplex scan Blood pressure <=160/90 mmHg Stable medication regimen for at least 6 months and not previously treated with ACE inhibitors Exclusion Criteria: Limiting coronary artery disease Renal Failure History of hypertension History of type 2 diabetes mellitus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bronwyn A Kingwell, PhD
Organizational Affiliation
Baker Heart Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia

12. IPD Sharing Statement

Citations:
PubMed Identifier
16670135
Citation
Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006 May 2;144(9):660-4. doi: 10.7326/0003-4819-144-9-200605020-00009.
Results Reference
result

Learn more about this trial

The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

We'll reach out to this number within 24 hrs